Clinical Trials List
2023-03-06 - 2030-12-31
Phase II
Recruiting4
ICD-10C50.911
Malignant neoplasm of unspecified site of right female breast
ICD-10C50.912
Malignant neoplasm of unspecified site of left female breast
ICD-10C50.919
Malignant neoplasm of unspecified site of unspecified female breast
ICD-10Z51.12
Encounter for antineoplastic immunotherapy
ICD-9174.9
Malignant neoplasm of female breast, unspecified
-
Trial Applicant
-
Sponsor
-
Trial scale
Multi-Regional Multi-Center
-
Update
2026/02/01
Investigators and Locations
Co-Principal Investigator
- Wen-Chi Shen Division of Hematology & Oncology
- Wen-Ling Kuo Division of General Surgery
- Chan-Keng Yang Division of Hematology & Oncology
- 周旭桓 Division of General Surgery
- Mengting Peng Division of Hematology & Oncology
- 沈士哲 Division of General Surgery
- 徐執中 Division of Hematology & Oncology
- Chi-Chang Yu Division of General Surgery
- 阮昱翔 Division of Radiology
- Shin-Cheh Chen Division of General Surgery
The Actual Total Number of Participants Enrolled
0 Recruiting
Co-Principal Investigator
- 林季宏 Division of Hematology & Oncology
- Wei-Wu Chen Division of Hematology & Oncology
- MING-YANG WANG Division of General Surgery
- 張端瑩 Division of Hematology & Oncology
- 羅喬 Division of General Surgery
- 李佳真 Division of Hematology & Oncology
- 陳怡君 Division of Hematology & Oncology
- WEI-LI MA Division of Hematology & Oncology
- 黃柏翔 Division of Hematology & Oncology
The Actual Total Number of Participants Enrolled
0 Recruiting
Co-Principal Investigator
- 林燕淑 Division of General Surgery
- Chi-Cheng Huang Division of General Surgery
- 賴亦貞 Division of Radiology
- 陳彥蓁 Division of General Surgery
- Chun-Yu Liu Division of General Internal Medicine
- 馮晉榮 Division of General Surgery
- Yi-Fang Tsai Division of General Surgery
- 邱仁輝 Division of General Surgery
- Ta-Chung Chao Division of Hematology & Oncology
- Jiun-I Lai Division of Hematology & Oncology
The Actual Total Number of Participants Enrolled
0 Recruiting
The Actual Total Number of Participants Enrolled
0 Recruiting
Condition/Disease
Objectives
Test Drug
Active Ingredient
Dosage Form
Dosage
Endpoints
Inclution Criteria
The Estimated Number of Participants
-
Taiwan
約20 participants
-
Global
160 participants